TM3 Therapeutics Appoints Peter Van Vlasselaer as Chairman of the Board

TM3 Therapeutics Appoints Peter Van Vlasselaer as Chairman of the Board

29.11.2017  TM3 Therapeutics, a spin-off of ACIES BIO, is a biopharmaceutical company focused on developing metabolite replacement therapies for rare, genetic neurological diseases.

TM3 Therapeutics announced today the appointment of Peter Van Vlasselaer, Ph.D. as Chairman of TM3’s Board of Directors. Dr. Van Vlasselaer is currently Chief Executive Officer of ARMO Biosciences. He is world-wide recognized as a serial entrepreneur with an outstanding track record of building successful biotech companies, and brings more than 20 years of experience in the biotech industry.

“As founder and co-founder, CEO and board member of several biotechnology companies, Peter has extensive experience in guiding companies from their early innovative research stage through commercialization of therapies. His insights will be invaluable for TM3 as we aim to become the leading company in coenzyme A disorders such as Pantothenate kinase-associated neurodegeneration (PKAN). We are thus very proud to welcome Peter as Chairman of our Board,” said Enej Kuscer, Ph.D., Co-founder and CEO of TM3.

You can read the whole announcement on BusinessWire.